Halazepam: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Protected "Halazepam": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{Drugbox|
{{Drugbox
|IUPAC_name = ''9-chloro-6-phenyl-2-(2,2,2-trifluoroethyl)-2,5-diazabicyclo''<br />''[5.4.0]undeca-5,8,10,12-tetraen-3-one''
| Watchedfields = changed
| image = Halazepam.svg
| verifiedrevid = 461743655
| width=220
| IUPAC_name = 7-chloro- 5-phenyl- 1-(2,2,2-trifluoroethyl) -1,3-dihydro- 2''H''-1,4-benzodiazepin- 2-one
| image2 = Halazepam3d.png
| image = Halazepam.png| width = 220
| CAS_number=23092-17-3
| image2 = Halazepam0.png
| ATC_prefix=N05
 
| ATC_suffix=BA13
<!--Clinical data-->
| ATC_supplemental=
| tradename =
| PubChem=31640
| Drugs.com = {{drugs.com|CONS|halazepam}}
| DrugBank=APRD01009
| MedlinePlus = a684001
| C=17 | H=12 | Cl=1 | F=3 | N=2 | O=1
| molecular_weight = 352.7
| bioavailability= ?
| metabolism = [[Liver|Hepatic]]
| elimination_half-life= ?
| excretion = [[Kidney|Renal]]
| pregnancy_category = ?
| pregnancy_category = ?
| legal_status = [[Schedule IV controlled substance|Schedule IV]] (US)
| legal_status = [[Schedule IV controlled substance|Schedule IV]] (US)
| routes_of_administration= Oral
| routes_of_administration = Oral
 
<!--Pharmacokinetic data-->
| bioavailability = ?
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 14 hours (drug), 50-100 hours (metabolites).
| excretion = [[Kidney|Renal]]
 
<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 23092-17-3
| ATC_prefix = N05
| ATC_suffix = BA13
| PubChem = 31640
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00801
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 29343
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 320YC168LF
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00338
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 970
 
<!--Chemical data-->
| C=17 | H=12 | Cl=1 | F=3 | N=2 | O=1
| molecular_weight = 352.7
| smiles = FC(F)(CN1C(CN=C(C2=CC=CC=C2)C3=C1C=CC(Cl)=C3)=O)F
| InChI = 1/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2
| InChIKey = WYCLKVQLVUQKNZ-UHFFFAOYAZ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WYCLKVQLVUQKNZ-UHFFFAOYSA-N
| synonyms = <small>9-chloro- 6-phenyl- 2-(2,2,2-trifluoroethyl)- 2,5-diazabicyclo[5.4.0] undeca- 5,8,10,12-tetraen -3-one</small>
}}
}}
'''Halazepam''' is a [[benzodiazepine]] derivative. It possesses [[anxiolytic]], [[anticonvulsant]], [[sedative]] and [[skeletal muscle relaxant]] properties. It is a trifluoromethyl derivative of [[nordazepam]].<ref name=derivation>{{cite journal | first = D. J. | last = Greenblatt | coauthors = A. Locniskar and R. I. Shader | date = [[June 12]], [[1982]] | title = Halazepam, another precursor of desmethyldiazepam | journal = Lancet | volume = 1 | issue = 8285 | pages = 1358-9 | id = {{PMID|6123659}}}}</ref> While its structure may be similar to [[chlordiazepoxide]] and [[diazepam]], it has both less toxicity and less tendency to cause paradoxical hostility and aggression than either of them.<ref name=kinder_gentler_benzo>{{cite journal | first = W. E. | last = Fann | coauthors = W. M. Pitts and J. C. Wheless | month = Mar-Apr | year = 1982 | title = Pharmacology, efficacy, and adverse effects of halazepam, a new benzodiazepine | journal = Pharmacotherapy | volume = 2 | issue = 2 | pages = 72-9 | id = {{PMID|6152591}}}}</ref>
__NOTOC__
==References==
{{SI}}
<div class="references-small"><references/></div>
{{CMG}}
==Overview==
 
'''Halazepam''' is a [[benzodiazepine]] derivative that was marketed under the brand names '''Paxipam''' in the United States,<ref name=DrugsH />  '''Alapryl''' in Spain,<ref name=DrugsA>{{cite web|title=Alapryl|url=http://www.drugs.com/international/alapryl.html|publisher=Drugs.com|accessdate=December 11, 2014}}</ref> and '''Pacinone''' in Portugal.<ref name=DrugsP>{{cite web|title=Pacinone|url=http://www.drugs.com/international/pacinone.html|publisher=Drugs.com|accessdate=December 11, 2014}}</ref>
 
==Medical uses==
Halazepam was used for the treatment of [[anxiety]].<ref name=DrugsH />
 
==Adverse effects==
Adverse effects include drowsiness, confusion, dizziness, and sedation.  Gastrointestinal side effects have also been reported including dry mouth and nausea.<ref name=DrugsH />
 
==Pharmacokinetics and pharmacodynamics==
Pharmacokinetics and pharmacodynamics were listed in ''Current Psychotherapeutic Drugs'' published in June 15, 1998 as follows:<ref>{{cite book|last1=Quitkin|first1=Frederick M.  ... |title=Current therapeutic drugs|date=1998|publisher=American Psychiatric Press|location=Washington|isbn=0880489944|page=166|edition=2nd ed.}}</ref>
 
{| class="wikitable"
|-
|Onset of action || Intermediate to slow
|-
| Plasma half life || 14 hr for parent drug and 30-100 hr for its metabolite
|-
| Peak plasma levels || 1-3 hr for parent drug and 3-6 hf for its metabolite
|-
| Metabolism || Metabolized into desmethyldiazepam and 3-hydroxyhalazepam (in the liver)
|-
| Excretion || Excreted through kidneys
|-
| Protein binding|| 98% bound to plasma protein
|}
 
==Regulatory Information==
Halazepam is classified as a [[Controlled_Substances_Act#Schedule_IV_controlled_substances|schedule 4]] [[controlled substance]] with a corresponding code 2762 by the [[Drug Enforcement Administration]] (DEA).<ref name=DEA>{{cite web|title=SCHEDULES OF CONTROLLED SUBSTANCES|url=http://www.gpo.gov/fdsys/pkg/CFR-2012-title21-vol9/xml/CFR-2012-title21-vol9-part1308.xml|publisher=Code of Federal Reguations|accessdate=December 12, 2014|pages=§ 1308.14 Schedule IV|date=2012-04-01}}</ref>
 
==Commercial production==
Halazepam was invented by Schlesinger Walter in the U.S. It was marketed as an anti-anxiety agent in 1981. However, Halazepam is not commercially available in the United States because it was withdrawn by its manufacturer for poor sales.<ref name=DrugsH>{{cite web|title=halazepam|url=http://www.drugs.com/mtm/halazepam.html|publisher=Drugs.com|accessdate=December 11, 2014}}</ref>
 
==See also==
==See also==
*[[nordazepam]]
*[[diazepam]]
*[[chlordiazepoxide]]
*[[Benzodiazepine]]s
*[[Benzodiazepine]]s
==External links==
*[[Nordazepam]]
* [http://www.inchem.org/documents/pims/pharm/pim160.htm Inchem - Halazepam]
*[[Diazepam]]
*[[Chlordiazepoxide]]
*[[Quazepam]]
 
==References==
{{Reflist|2}}


{{Benzodiazepines}}
{{Benzodiazepines}}
{{Anxiolytics}}
{{Anxiolytics}}
[[Category:Anticonvulsants]]
 
[[Category:Anxiolytics]]
[[Category:Benzodiazepines]]
[[Category:Benzodiazepines]]
[[Category:Hypnotics]]
[[Category:Organochlorides]]
[[Category:Muscle relaxants]]
[[Category:Organofluorides]]
[[Category:Sedatives]]
[[Category:Lactams]]
 
[[Category:Drug]]
 
{{pharma-stub}}
 
[[pt:Halazepam]]
[[sv:Halazepam]]
{{WikiDoc Sources}}

Latest revision as of 14:24, 13 April 2015

Halazepam
Clinical data
Synonyms9-chloro- 6-phenyl- 2-(2,2,2-trifluoroethyl)- 2,5-diazabicyclo[5.4.0] undeca- 5,8,10,12-tetraen -3-one
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa684001
Pregnancy
category
  • ?
Routes of
administration		Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability?
MetabolismHepatic
Elimination half-life14 hours (drug), 50-100 hours (metabolites).
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC17H12ClF3N2O
Molar mass352.7
3D model (JSmol)
  (verify)

WikiDoc Resources for Halazepam

Articles

Most recent articles on Halazepam

Most cited articles on Halazepam

Review articles on Halazepam

Articles on Halazepam in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Halazepam

Images of Halazepam

Photos of Halazepam

Podcasts & MP3s on Halazepam

Videos on Halazepam

Evidence Based Medicine

Cochrane Collaboration on Halazepam

Bandolier on Halazepam

TRIP on Halazepam

Clinical Trials

Ongoing Trials on Halazepam at Clinical Trials.gov

Trial results on Halazepam

Clinical Trials on Halazepam at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Halazepam

NICE Guidance on Halazepam

NHS PRODIGY Guidance

FDA on Halazepam

CDC on Halazepam

Books

Books on Halazepam

News

Halazepam in the news

Be alerted to news on Halazepam

News trends on Halazepam

Commentary

Blogs on Halazepam

Definitions

Definitions of Halazepam

Patient Resources / Community

Patient resources on Halazepam

Discussion groups on Halazepam

Patient Handouts on Halazepam

Directions to Hospitals Treating Halazepam

Risk calculators and risk factors for Halazepam

Healthcare Provider Resources

Symptoms of Halazepam

Causes & Risk Factors for Halazepam

Diagnostic studies for Halazepam

Treatment of Halazepam

Continuing Medical Education (CME)

CME Programs on Halazepam

International

Halazepam en Espanol

Halazepam en Francais

Business

Halazepam in the Marketplace

Patents on Halazepam

Experimental / Informatics

List of terms related to Halazepam

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Halazepam is a benzodiazepine derivative that was marketed under the brand names Paxipam in the United States,[1] Alapryl in Spain,[2] and Pacinone in Portugal.[3]

Medical uses

Halazepam was used for the treatment of anxiety.[1]

Adverse effects

Adverse effects include drowsiness, confusion, dizziness, and sedation. Gastrointestinal side effects have also been reported including dry mouth and nausea.[1]

Pharmacokinetics and pharmacodynamics

Pharmacokinetics and pharmacodynamics were listed in Current Psychotherapeutic Drugs published in June 15, 1998 as follows:[4]

Onset of action Intermediate to slow
Plasma half life 14 hr for parent drug and 30-100 hr for its metabolite
Peak plasma levels 1-3 hr for parent drug and 3-6 hf for its metabolite
Metabolism Metabolized into desmethyldiazepam and 3-hydroxyhalazepam (in the liver)
Excretion Excreted through kidneys
Protein binding 98% bound to plasma protein

Regulatory Information

Halazepam is classified as a schedule 4 controlled substance with a corresponding code 2762 by the Drug Enforcement Administration (DEA).[5]

Commercial production

Halazepam was invented by Schlesinger Walter in the U.S. It was marketed as an anti-anxiety agent in 1981. However, Halazepam is not commercially available in the United States because it was withdrawn by its manufacturer for poor sales.[1]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 "halazepam". Drugs.com. Retrieved December 11, 2014.
  2. ↑ "Alapryl". Drugs.com. Retrieved December 11, 2014.
  3. ↑ "Pacinone". Drugs.com. Retrieved December 11, 2014.
  4. ↑ Quitkin, Frederick M. ... (1998). Current therapeutic drugs (2nd ed. ed.). Washington: American Psychiatric Press. p. 166. ISBN 0880489944.
  5. ↑ "SCHEDULES OF CONTROLLED SUBSTANCES". Code of Federal Reguations. 2012-04-01. pp. § 1308.14 Schedule IV. Retrieved December 12, 2014.

Template:Benzodiazepines Template:Anxiolytics

Retrieved from "https://www.wikidoc.org/index.php?title=Halazepam&oldid=1086527"